Novartis AG | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (99)

View All

Latest Posts

About This Stock More About This Stock
Week In Review: China Biopharmas Book $9 Billion In Deals During JP Morgan Conference Week
Article By: ChinaBio® Today
Saturday, January 13, 2024 1:20 PM EDT
Shanghai Argo Biopharma entered 2 agreements with Novartis, out-licensing four next-gen RNAi therapeutics for $185 million upfront and a total value of $4.2 billion. Additionally, Ambrx Biopharma will be acquired by Johnson & Johnson for $2 billion.
In this article: GSK, JNJ, NVS, BAYRY, BNTX, PRAX, AMAM, HLVX Also: TAK
Read
Bullish Continuation In '24? 3 Market Areas To Watch
Article By: Zacks Investment Research
Wednesday, January 10, 2024 11:00 PM EDT
This article discusses 3 market areas that should outperform dramatically over the next 12 months...
In this article: BMY, NVO, NVS, CYTK, IBB, MSFT, NVDA, IWM, META, GOOGL, KRTX
Read
Week In Review: 2024 Kicks Off With Three Deals Worth A Total Of $4 Billion
Article By: ChinaBio® Today
Sunday, January 7, 2024 7:20 AM EDT
Suzhou Ribo Life Science formed a collaboration with Boehringer Ingelheim in a deal that could be worth up to $2 billion. Additionally, Allorion Therapeutics has out-licensed global rights (ex-China) for AVZO-021 to Avenzo Therapeutics.
In this article: NVS, RHHBY, TSVT Also: BNTX, APLM
Read
Week In Review: Legend Partners DLL3 CAR-T Candidate With Novartis In $1.2 Billion Deal
Article By: ChinaBio® Today
Saturday, November 18, 2023 2:00 PM EDT
Legend Biotech partnered its DLL3 CAR-T candidates to Novartis in a $1.2 billion agreement, with $100 million offered upfront. Novartis will own worldwide rights to develop, manufacture, and commercialize the DLL3 group of cell therapies.
In this article: NVS, TBPH, LEGN, VTRS, APLM Also: WXXWY
Read
Week In Review: Everest Acquires Novel Autoimmune Therapy In $132 Million Agreement
Article By: ChinaBio® Today
Saturday, September 23, 2023 2:19 PM EDT
Shanghai Everest Medicines acquired China/Asian rights to a novel therapy for autoimmune diseases from Kezar Life Sciences of South San Francisco in a deal worth $132.5 million. The company will make an upfront payment of $7 million to Kezar.
In this article: NVS, BGNE, KZR Also: BMY, OCUL
Read
All Posts

Latest Tweets for $NVS

No tweets yet!

PARTNER HEADLINES

$NVS

Comments Status Updates
Daily Stock Pick: Novartis
Bill Myers • 10/4/2019 3:12:59 PM

I like $NVS.

OncoSec Raising Its Profile In Fight Against Cancer
BreakingBad News • 9/6/2017 3:48:05 PM

More good news on the war against #Cancer, thanks. #Novartis also has made great progress against B-cell acute lymphoblastic leukemia: www.talkmarkets.com/.../finally-a-cure-for-cancer $ONCS $NVS

Finally… A Cure for Cancer?
BreakingBad News • 9/6/2017 3:30:54 PM

Lot of good news against the war on #Cancer. Also just read this about #OncoSec: www.talkmarkets.com/.../oncosec-raising-its-profile-in-fight-against-cancer $ONCS $NVS

Novartis Receives FDA Approval For An Acute Myeloid Leukemia Drug
Terry Chrisomalis • 5/1/2017 12:22:24 AM

Yes it does indeed. #Novartis has been doing very well lately. $NVS

Novartis Receives FDA Approval For An Acute Myeloid Leukemia Drug
Danielle Rogers • 4/30/2017 5:29:49 PM

Triple the effectiveness over a placebo looks very promising! $NVS

Novartis-Backed Ionis Subsidiary Akcea Maps A $100M IPO As It Steers A Lead Drug To Regulators
Linda Willis • 3/28/2017 2:56:54 AM

Sounds good to me! $NVS $IONS

1 to 6 of 6 comments